VIRGINIA RETIREMENT SYSTEMS ET Al Sells 25,600 Shares of Indivior PLC $INDV

VIRGINIA RETIREMENT SYSTEMS ET Al trimmed its holdings in shares of Indivior PLC (NASDAQ:INDV) by 31.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 55,600 shares of the company’s stock after selling 25,600 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Indivior were worth $1,993,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. HighTower Advisors LLC acquired a new position in shares of Indivior in the 2nd quarter valued at about $3,409,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Indivior during the 2nd quarter valued at about $7,988,000. Cookson Peirce & Co. Inc. bought a new stake in shares of Indivior during the 2nd quarter valued at about $1,390,000. Two Seas Capital LP raised its stake in Indivior by 5.5% during the third quarter. Two Seas Capital LP now owns 3,671,072 shares of the company’s stock worth $131,608,000 after acquiring an additional 191,579 shares during the period. Finally, Wellington Management Group LLP acquired a new stake in Indivior during the second quarter worth about $1,870,000. 60.33% of the stock is currently owned by institutional investors.

Indivior Stock Performance

Shares of INDV opened at $36.40 on Wednesday. Indivior PLC has a 1 year low of $27.68 and a 1 year high of $42.81. The company has a market cap of $4.30 billion, a price-to-earnings ratio of 8.54 and a beta of 0.84. The firm has a fifty day moving average of $35.19 and a 200-day moving average of $35.64.

Indivior (NASDAQ:INDV) last released its quarterly earnings results on Thursday, October 29th. The company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.06 by $0.26. Indivior had a net margin of 32.75% and a negative return on equity of 418.04%. The business had revenue of $356.00 million during the quarter, compared to analyst estimates of $329.35 million. Analysts predict that Indivior PLC will post 3.66 EPS for the current year.

Indivior Announces Dividend

The company also recently announced a special dividend, which will be paid on Friday, November 6th. Shareholders of record on Friday, October 30th will be paid a dividend of $8.13 per share. The ex-dividend date of this dividend is Tuesday, November 3rd.

Analyst Ratings Changes

INDV has been the topic of a number of recent research reports. Weiss Ratings cut shares of Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, September 24th. Barclays upped their target price on Indivior from $43.00 to $45.00 and gave the company an “overweight” rating in a report on Wednesday, October 28th. Wall Street Zen cut Indivior from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Zacks Research upgraded Indivior from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 2nd. Finally, Craig Hallum reissued a “buy” rating and issued a $53.00 price target on shares of Indivior in a report on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, Indivior currently has a consensus rating of “Buy” and an average price target of $46.40.

Insider Buying and Selling

In other news, CAO Woodrow D. Anderson bought 1,500 shares of the firm’s stock in a transaction on Thursday, August 27th. The stock was purchased at an average price of $35.69 per share, for a total transaction of $53,535.00. Following the transaction, the chief accounting officer owned 27,638 shares in the company, valued at approximately $986,400.22. This trade represents a 5.74% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.74% of the company’s stock.

About Indivior

Indivior PLC (NASDAQ:INDV) is a global pharmaceutical company focused on developing and commercializing medicines for substance use disorders and serious mental health conditions. Its portfolio is centered on treatments for opioid use disorder, opioid overdose, and related medical needs.

The company’s principal products include Sublocade, an extended-release buprenorphine injection for opioid use disorder; Suboxone, a buprenorphine and naloxone treatment available in film and other formulations; and Opvee, a nalmefene nasal spray intended for the emergency treatment of known or suspected opioid overdose.